Literature DB >> 9869594

In vitro activities of six new fluoroquinolones against Brucella melitensis.

I Trujillano-Martín1, E García-Sánchez, I M Martínez, M J Fresnadillo, J E García-Sánchez, J A García-Rodríguez.   

Abstract

We have tested the in vitro activities of eight fluoroquinolones against 160 Brucella melitensis strains. The most active was sitafloxacin (MIC at which 90% of the isolates are inhibited [MIC90], 0.12 microg/ml). In decreasing order, the activities (MIC90s) of the rest of the tested fluoroquinolones were as follows: levofloxacin, 0.5 microg/ml; ciprofloxacin, trovafloxacin, and moxifloxacin, 1 microg/ml; and ofloxacin, grepafloxacin, and gatifloxacin, 2 microg/ml.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9869594      PMCID: PMC89049     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Lack of effective bactericidal activity of new quinolones against Brucella spp.

Authors:  J A García-Rodriguez; J E García Sánchez; I Trujillano
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

2.  Susceptibility of Brucella melitensis to fluoroquinolones.

Authors:  S M Qadri; M Akhtar; Y Ueno; M B al-Sibai
Journal:  Drugs Exp Clin Res       Date:  1989

3.  In vitro activity of BAY y 3118, and nine other antimicrobial agents against anaerobic bacteria.

Authors:  J A García-Rodríguez; J E García-Sánchez; I Trujillano-Martín; E García-Sánchez; M I García-García; M J Fresnadillo-Martínez
Journal:  J Chemother       Date:  1995-06       Impact factor: 1.714

4.  In vitro activity of ciprofloxacin against Brucella melitensis.

Authors:  M Gobernado; E Cantón; M Santos
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

5.  Comparison of three different regimens in the treatment of acute brucellosis: a multicenter multinational study.

Authors:  G Acocella; A Bertrand; J Beytout; J B Durrande; J A Garcia Rodriguez; J Kosmidis; M Micoud; M Rey; M Rodriguez Zapata; J Roux
Journal:  J Antimicrob Chemother       Date:  1989-03       Impact factor: 5.790

6.  Antibacterial activity of lomefloxacin against Brucella melitensis.

Authors:  S M Qadri; S al-Sedairy; Y Ueno
Journal:  Diagn Microbiol Infect Dis       Date:  1990 May-Jun       Impact factor: 2.803

Review 7.  Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

Authors:  W A Craig
Journal:  Clin Infect Dis       Date:  1998-01       Impact factor: 9.079

8.  Effect of ciprofloxacin on intracellular organisms: in-vitro and in-vivo studies.

Authors:  C S Easmon; J P Crane; A Blowers
Journal:  J Antimicrob Chemother       Date:  1986-11       Impact factor: 5.790

9.  Susceptibility of Brucella melitensis to the new fluoroquinolone PD 131628: comparison with other drugs.

Authors:  S M Qadri; Y Ueno
Journal:  Chemotherapy       Date:  1993 Mar-Apr       Impact factor: 2.544

10.  Susceptibilities of Brucella melitensis isolates to clinafloxacin and four other new fluoroquinolones.

Authors:  J A García-Rodríguez; J E García Sánchez; I Trujillano; E García Sánchez; M I García García; M J Fresnadillo
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

View more
  9 in total

Review 1.  Use of aminoglycosides in treatment of infections due to intracellular bacteria.

Authors:  M Maurin; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

Review 2.  Quinolones for treatment of human brucellosis: critical review of the evidence from microbiological and clinical studies.

Authors:  Matthew E Falagas; Ioannis A Bliziotis
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

3.  Broth microdilution susceptibility testing of Brucella species: quality control limits for ten antimicrobial agents against three standard quality control strains.

Authors:  Steven D Brown; Maria M Traczewski
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

4.  Species-specific PCR for the Diagnosis and Determination of Antibiotic Susceptibilities of Brucella Strains Isolated from Tehran, Iran.

Authors:  Gholam Reza Irajian; Faramarz Masjedian Jazi; Reza Mirnejad; Vahhab Piranfar; Taghi Zahraei Salehi; Noor Amir Mozafari; Ehsanollah Ghaznavi-Rad; Mahmoud Khormali
Journal:  Iran J Pathol       Date:  2016

5.  Effect of Medium pH on Antibiotic Activity against Syrian Brucella spp. Isolates.

Authors:  Ayman Al-Mariri; Mazen Safi
Journal:  Iran J Med Sci       Date:  2013-09

6.  In vitro antibiotic susceptibility testing of Brucella isolates from Egypt between 1999 and 2007 and evidence of probable rifampin resistance.

Authors:  Mohamed Abdel-Maksoud; Brent House; Momtaz Wasfy; Bassem Abdel-Rahman; Guillermo Pimentel; Gehan Roushdy; Erica Dueger
Journal:  Ann Clin Microbiol Antimicrob       Date:  2012-08-28       Impact factor: 3.944

7.  Efficacy evaluation of some antibiotics against syrian brucella spp isolates, in vitro.

Authors:  Mazen Safi; Ayman Al-Mariri
Journal:  Braz J Microbiol       Date:  2012-06-01       Impact factor: 2.476

8.  Identification and determination of antibiotic susceptibilities of Brucella strains isolated from patients in van, Turkey by conventional and molecular methods.

Authors:  Mehmet Parlak; Hüseyin Güdücüoğlu; Yasemin Bayram; Aytekin Çıkman; Cenk Aypak; Selçuk Kılıç; Mustafa Berktaş
Journal:  Int J Med Sci       Date:  2013-08-22       Impact factor: 3.738

9.  In vitro synergistic activity of antibiotic combinations against Brucella melitensis using E-test methodology.

Authors:  Selcuk Kilic; Murat Dizbay; Kenan Hizel; Dilek Arman
Journal:  Braz J Microbiol       Date:  2008-06-01       Impact factor: 2.476

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.